Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy: The PORTO trial

Circulation Journal

Volumn 78, Issue 3, 2014, Pages 679-684

  Pelliccia, Francesco ^a   Rosano, Giuseppe ^b   Marazzi, Giuseppe ^b   Vitale, Cristiana ^b,f   Spoletini, Ilaria ^b   Franzoni, Ferdinando ^c   Speziale, Giuseppe ^d   Polacco, Marina ^a   Greco, Cesare ^a   Gaudio, Carlo ^a,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Anthea Hospital GVM Care and Research   (Italy)

^e Eleonora Lonillard Spencer Cenci Foundation   (Italy)

^f Laboratory of Vascular Physiology IRCCS San Raffaele   (United Kingdom)

Author keywords

Clopidogrel; Coronary artery disease; Percutaneous coronary intervention; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; PITAVASTATIN; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; TICLOPIDINE;

AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRROLES; QUINOLINES; TICLOPIDINE;

EID: 84894466932     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1216     Document Type: Article

References (34)

1. Alexopoulos D, Xanthopoulou I, Tsigkas G, Damelou A, Theodoropoulos KC, Kassimis G, et al. Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST-elevation myocardial infarction. Circ J 2012; 76: 2183-2187
2. Motoda C, Ueda H, Hayashi Y, Toyofuku M, Okimoto T, Otsuka M, et al. Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina. Circ J 2012; 76: 641-649
3. Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: Myth or reality? J Am Coll Cardiol 2007; 50: 296-298
4. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-1263
5. Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, et al; CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: Perspectives from the CREDO-Kyoto registry cohort-2. Circ J 2012; 76: 1369-1379
6. Takashima H, Ozaki Y, Morimoto T, Kimura T, Hiro T, Miyauchi K, et al; JAPAN-ACS Investigators. Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: The JAPANACS subanalysis study. Circ J 2012; 76: 2840-2847
7. Wang TJ, Yang YJ, Xu B, Zhang Q, Jin C, Tang Y, et al. Atorvastatin accelerates both neointimal coverage and re-endothelialization after sirolimus-eluting stent implantation in a porcine model: New findings from optical coherence tomography and pathology. Circ J 2012; 76: 2561-2571
8. Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: A prospective study of 2-years' follow-up. Circ J 2012; 76: 2755-2762
9. Lee SW, Hau WK, Kong SL, Chan KK, Chan PH, Lam SC, et al. Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: The VENUS study. Circ J 2012; 76: 2662-2672
10. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232
11. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005; 19: 117-125
12. Isley W. Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today 2001; 37: 587-594
13. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase: Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002; 52: 745-753
14. Fujino H, Saito S, Tsunemari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004; 34: 961-971
15. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-146
16. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005; 6: 800-807
17. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28: 315-322
18. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-2164
19. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011; 305: 1097-1105
20. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995; 311: 1145-1148
21. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003; 107: 32-37
22. Malmström RE, Ostergren J, Jørgensen L, Hjemdahl P; CASTOR investigators. Influence of statin treatment on platelet inhibition by clopidogrel: A randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. Eur J Clin Invest 2005; 35: 476-481
23. Vinholt P, Poulsen TS, Korsholm L, Kristensen SR, Hallas J, Damkier P, et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. J Intern Med 2009; 266: 457-466
24. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 2004; 164: 2051-2057
25. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-1338
26. Park Y, Jeong YH, Tantry US, Ahn JH, Kwon TJ, Park JR, et al. Accelerated platelet inhibition by switching from atorvastatin to a non- CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J 2012; 33: 2151-2162
27. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005; 33: 537-546
28. Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006; 23: 506-512
29. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581
30. Ose L. Pitavastatin: A distinctive lipid lowering drug. Clin Lipidol 2010; 5: 309-323
31. Catapano AL. Pitavastatin: Pharmacological profile from early phase studies. Atheroscler Suppl 2010; 11: 3-7
32. Marin F, Gonzalez-Conejero R, Capranzano P, Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009; 54: 1041-1057
33. Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, et al; McLordd Group. Relationship between CYP2C19 loss-offunction polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. Circ J 2013; 77: 1436-1444
34. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship gene polymorphisms clinical outcomes. J Am Coll Cardiol 2011; 57: 2474-2483.